Key Findings:  Data reveals significant differences in mRNA expression of CB1 receptor sites in a rat model of PD. Furthermore, the group of rats treated with arachidonyl-2'-chloroethylamide (ACEA), a full CB1 cannabinoid receptor agonist, experienced a significant reduction in abnormal involuntary movements.
Type of Study:  Animal Study
Study Result:  Positive
Cannabinoids Studied:  Synthetic Cannabinoid (unspecified)
Phytocannabinoid Source:  Not Applicable